CATALYST PHARMACEUTICALS, INC. Material Event - What Happened

This report explains the latest news from Catalyst Pharmaceuticals in plain English. Here is the "need-to-know" breakdown regarding the major announcements from May 6–7, 2026.

1. What happened?

Catalyst Pharmaceuticals has agreed to be bought by Angelini Pharma, a private Italian drug company, in an all-cash deal. Once the deal closes, Catalyst will stop trading on the stock market and become a subsidiary of Angelini Pharma.

At the same time, Catalyst settled a patent lawsuit with Hetero USA, Inc. regarding FIRDAPSE®, the company’s main drug for treating Lambert-Eaton myasthenic syndrome (LEMS).

2. Why does the patent settlement matter?

This settlement ends the legal battle over Catalyst’s patents. Hetero now acknowledges that Catalyst’s patents are valid and has agreed not to launch a generic version of the drug in the U.S. until January 1, 2035, unless specific conditions are met.

Why this matters: For drug companies, patent protection is the primary way they secure future revenue. By winning this settlement, Catalyst has effectively blocked generic competition for nearly a decade. This protects the long-term value of the FIRDAPSE® franchise and was a key factor in the price Angelini Pharma agreed to pay for the company.

3. Why is the company being sold?

Catalyst focuses on treatments for rare diseases. Angelini Pharma is looking to expand its global footprint by acquiring Catalyst’s specialized products and its established distribution network. By buying Catalyst, Angelini gains full control of the FIRDAPSE® franchise and deep expertise in the U.S. rare disease market.

4. What does this mean for investors?

• The "Cash-Out": Catalyst stockholders will receive $31.50 in cash for each share they own. This provides immediate value but caps any potential for your shares to grow further.
• The "Spread": The gap between the current stock price and the $31.50 offer price is known as the "merger arbitrage spread." This gap exists because there is always a small risk that regulators might block the deal or that shareholders might vote against it.
• Shift in Strategy: Since this is an all-cash deal, the focus for investors shifts from the company’s daily operational growth to the logistics of the buyout. You are no longer betting on the company’s long-term performance, but rather on the successful completion of this acquisition.

5. What happens next?

The deal is expected to close in the third quarter of 2026, provided that standard conditions are met. The process includes:

• Stockholder Vote: Catalyst will hold a special meeting where a majority of shareholders must vote in favor of the deal.
• Regulatory Approval: Government regulators must review the transaction to ensure it complies with competition laws.
• Stay Informed: Catalyst will file a document with the SEC called a "proxy statement." This will contain the full background of the deal, the board’s reasoning for recommending it, and instructions on how to vote your shares. The company has not yet provided specific dates for the shareholder meeting, so keep an eye on your brokerage notifications for that filing.

Final Thought for Investors: If you currently hold shares, your primary decision is whether to wait for the $31.50 payout or sell now to lock in your current gains. If you are considering buying, remember that your profit potential is limited to the difference between your purchase price and the $31.50 offer, and you are taking on the risk that the deal could fall through.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research or consult with a professional before making investment decisions.